8. Medulloblastoma

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ross Pinkerton

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch8

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Pinkerton, R. (2013) Medulloblastoma, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch8

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. Royal Children's Hospital, Brisbane, QLD, Australia

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309

SEARCH

Keywords:

  • brain;
  • medulloblastoma;
  • single-arm studies;
  • tumor

Summary

The evolution of medulloblastoma therapy is particularly complex and in the interpretation of results, one needs to take account of major changes that have occurred in radiology, anesthesia, neurosurgery, radiation, and medical oncology. In the first studies conducted by the International Society of Paediatric Oncology (SIOP) and the Radiation Therapy Oncology Group (RTOG), preoperative CT scan was the only mandatory imaging study required for staging. In subsequent studies, postoperative imaging and myelograms were requested but not always performed. Introduction of mandatory MRI scan of the brain and the spine only became standard in recent protocols. Recent transcriptional profiling studies have suggested the existence of distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. It is likely that the design of future studies will essentially be nonrandomized and that progress in the management of medulloblastoma will be based on the results of single-arm studies.